Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Gustave Roussy, Cancer Campus, Grand Paris
The Netherlands Cancer Institute
UNICANCER
GlaxoSmithKline
Ludwig Institute for Cancer Research
Asan Medical Center
National Institutes of Health Clinical Center (CC)
Centre Georges Francois Leclerc
Ludwig Institute for Cancer Research
Yale University
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
AstraZeneca